Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
GlobalData on MSN21h
BridgeBio Oncology and Helix enter definitive merger agreementBridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
Evercore ISI analyst Cory Kasimov maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) yesterday and set a price target of ...
Hosted on MSN10h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...
The end of the last decade brought record highs in pharmaceutical M&A as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback